| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/TRF.13868 |
| P698 | PubMed publication ID | 27731496 |
| P2093 | author name string | Shan Yuan | |
| Shirong Wang | |||
| P2860 | cites work | The EBMT activity survey 2008: impact of team size, team density and new trends | Q43754303 |
| Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization | Q44433507 | ||
| Fludarabine combination regimen severely affected peripheral blood stem cell mobilization | Q44903480 | ||
| Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma | Q44953920 | ||
| Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients | Q45752095 | ||
| Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma | Q45814461 | ||
| Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. | Q45936276 | ||
| Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization | Q46089696 | ||
| Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost | Q47818018 | ||
| Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma | Q47913355 | ||
| Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma | Q47951335 | ||
| Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma | Q48011116 | ||
| Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. | Q51705517 | ||
| Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. | Q51776428 | ||
| Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. | Q53083681 | ||
| The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF | Q56986459 | ||
| How I treat patients who mobilize hematopoietic stem cells poorly | Q28245316 | ||
| Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data | Q33543723 | ||
| Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy | Q33861711 | ||
| European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. | Q34194325 | ||
| Defining a Therapeutic Dose of Peripheral Blood Stem Cells | Q35174810 | ||
| Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. | Q36428104 | ||
| Improving stem cell mobilization strategies: future directions | Q37367235 | ||
| Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration | Q37424430 | ||
| Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor. | Q37707195 | ||
| Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization | Q37809734 | ||
| Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept | Q37943423 | ||
| Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations | Q38154080 | ||
| Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution | Q38422883 | ||
| Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients | Q38808625 | ||
| Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma | Q40201943 | ||
| G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. | Q40724468 | ||
| Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. | Q40786200 | ||
| Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study | Q41003137 | ||
| Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol | Q43246777 | ||
| Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio | Q43282877 | ||
| Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma | Q43442164 | ||
| Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent | Q43563982 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 13-23 | |
| P577 | publication date | 2016-10-12 | |
| P1433 | published in | Transfusion | Q15758500 |
| P1476 | title | How do we mobilize and collect autologous peripheral blood stem cells? | |
| P478 | volume | 57 |
| Q49887823 | Autologous hematopoietic progenitor cell mobilization and collection in adult patients presenting with multiple myeloma and lymphoma: A position-statement from the Turkish Society of Apheresis (TSA). |
| Q47447522 | Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG). |
| Q46654811 | Dose capping of plerixafor in patients weighing more than 100 kg at one vial led to successful mobilization outcomes and significant cost savings |
| Q52319493 | Expression of adhesion molecules on CD34+ cells from steady-state bone marrow before and after mobilization and their association with the yield of CD34+ cells. |
| Q91813144 | Human Periapical Cyst-Derived Stem Cells Can Be A Smart "Lab-on-A-Cell" to Investigate Neurodegenerative Diseases and the Related Alteration of the Exosomes' Content |
| Q33652381 | Mobilization, Isolation and Characterization of Stem Cells from Peripheral Blood: a Systematic Review |
| Q48251589 | Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score |
Search more.